Caroline Pignatelli of Cooley has entered an appearance Outlook Therapeutics Inc., its CEO and CFO in a pending securities class action. The complaint, filed Nov. 3 in New Jersey District Court by Pomerantz LLP and Bronstein, Gewirtz & Grossman, contends that the defendants failed to disclose that there was a lack of substantial evidence supporting Outlook's 'ONS-5010' drug as treatment for wet age-related macular degeneration. The case, assigned to U.S. District Judge Madeline Cox Arleo, is 2:23-cv-21862, Alsaidi v. Outlook Therapeutics, Inc. et al.
Biotech & Pharmaceuticals
December 15, 2023, 9:10 AM